Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Adams Diversified Equity Fund Inc.

Adams Diversified Equity Fund Inc. decreased its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 9.2% during the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 19,700 shares of the biopharmaceutical company's stock after selling 2,000 shares during the period. Adams Diversified Equity Fund Inc.'s holdings in Regeneron Pharmaceuticals were worth $12,494,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in REGN. Marietta Wealth Management LLC increased its stake in shares of Regeneron Pharmaceuticals by 30.2% during the 1st quarter. Marietta Wealth Management LLC now owns 10,778 shares of the biopharmaceutical company's stock worth $6,836,000 after purchasing an additional 2,501 shares in the last quarter. Pamalican Asset Management Ltd acquired a new stake in Regeneron Pharmaceuticals during the 4th quarter valued at $4,915,000. Intact Investment Management Inc. purchased a new position in Regeneron Pharmaceuticals during the fourth quarter worth $356,000. Rhenman & Partners Asset Management AB raised its holdings in shares of Regeneron Pharmaceuticals by 11.4% in the fourth quarter. Rhenman & Partners Asset Management AB now owns 43,457 shares of the biopharmaceutical company's stock worth $30,956,000 after acquiring an additional 4,457 shares during the last quarter. Finally, GAMMA Investing LLC raised its holdings in shares of Regeneron Pharmaceuticals by 89,825.0% in the first quarter. GAMMA Investing LLC now owns 815,620 shares of the biopharmaceutical company's stock worth $517,291,000 after acquiring an additional 814,713 shares during the last quarter. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of analysts recently commented on REGN shares. Morgan Stanley dropped their price objective on Regeneron Pharmaceuticals from $958.00 to $755.00 and set an "overweight" rating for the company in a research report on Monday, June 2nd. Truist Financial decreased their price target on shares of Regeneron Pharmaceuticals from $975.00 to $940.00 and set a "buy" rating on the stock in a research note on Wednesday, April 30th. Canaccord Genuity Group upgraded shares of Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a report on Tuesday, April 22nd. Robert W. Baird reduced their price objective on shares of Regeneron Pharmaceuticals from $759.00 to $652.00 and set a "neutral" rating on the stock in a research note on Friday, April 25th. Finally, Cantor Fitzgerald started coverage on shares of Regeneron Pharmaceuticals in a research report on Tuesday, April 22nd. They set an "overweight" rating and a $695.00 target price on the stock. One analyst has rated the stock with a sell rating, six have issued a hold rating, sixteen have issued a buy rating and three have issued a strong buy rating to the company's stock. According to MarketBeat.com, Regeneron Pharmaceuticals currently has a consensus rating of "Moderate Buy" and an average price target of $822.58.

Regeneron Pharmaceuticals Trading Up 0.1%

Shares of Regeneron Pharmaceuticals stock traded up $0.71 during trading hours on Thursday, hitting $521.00. The company's stock had a trading volume of 965,467 shares, compared to its average volume of 894,581. Regeneron Pharmaceuticals, Inc. has a 1-year low of $476.49 and a 1-year high of $1,211.20. The company has a market capitalization of $56.25 billion, a PE ratio of 13.26, a P/E/G ratio of 1.91 and a beta of 0.31. The company has a quick ratio of 4.03, a current ratio of 4.93 and a debt-to-equity ratio of 0.09. The business has a fifty day moving average of $555.86 and a 200 day moving average of $636.54.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $8.83 by ($0.61). Regeneron Pharmaceuticals had a net margin of 31.94% and a return on equity of 15.27%. The firm had revenue of $3.03 billion for the quarter, compared to analysts' expectations of $3.40 billion. During the same quarter in the prior year, the business earned $9.55 EPS. The company's revenue for the quarter was down 3.7% on a year-over-year basis. As a group, equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, June 6th. Stockholders of record on Tuesday, May 20th were paid a $0.88 dividend. The ex-dividend date was Tuesday, May 20th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.68%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is presently 8.96%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.